AR061653A1 - Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3) - Google Patents
Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3)Info
- Publication number
- AR061653A1 AR061653A1 ARP070102832A ARP070102832A AR061653A1 AR 061653 A1 AR061653 A1 AR 061653A1 AR P070102832 A ARP070102832 A AR P070102832A AR P070102832 A ARP070102832 A AR P070102832A AR 061653 A1 AR061653 A1 AR 061653A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- optionally substituted
- carbocyclyl
- carbamoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
La presente también se refiere a formulaciones farmacéuticas que contienen dicho compuesto y al uso de dicho compuesto en terapia, para trastornos cognitivos, diabetes, osteoporosis. La presente se refiere además a un proceso para la preparacion del compuesto de formula (1). Reivindicacion 1: Un compuesto de formula (1), donde A es heterociclilo o carbociclilo; donde dicho heterociclilo o carbociclilo está opcionalmente sustituido en carbono con uno o más R1 y donde si dicho heterociclilo contiene una porcion -NH-, ese nitrogeno puede estar opcionalmente sustituido con un grupo -R5-R7, con la salvedad de que dicho carbociclilo no es fenilo; R1 se selecciona entre halo, nitro, ciano, hidroxi, amino, sulfamoilo, carbamoilo, alquilo C1- 3, un carbociclilo, un heterociclilo y un grupo -R6-R7, donde dicho alquilo C1-3 está opcionalmente sustituido con uno o más halo y donde dicho carbociclilo o heterociclilo opcionalmente forma un sistema anular conjugado junto con A; R2 se selecciona entre halo, nitro, trifluorometilo, trifluorometoxi y ciano; R3 se seleccione entre metilo, alquilo C6, alquenilo C6, alquinilo C6, un carbociclilo no aromático de 6 miembros y un heterociclilo no aromático de 6 miembros, donde dicho alquilo C6, alquenilo C6, alquinilo C6, carbociclilo o heterociclilo está opcionalmente sustituido con uno o más halo, cieno, trifluorometoxi, haloalquilo C1-3 o alquilo C1-3; R4 se selecciona entre hidrogeno, alquilo C1-3, ciano y haloalquilo C1-3, donde dicho alquilo C1-3 o haloalquilo C1-3 está opcionalmente sustituido con uno o más OR8; donde R8 se selecciona independientemente entre hidrogeno, alquilo C1-6 o haloalquilo C1-6; R5 se selecciona entre -C(O)N(R9)-, -S(O)z-, -SO2N(R10)-, -SO2O- , -C(O)-, -C(O)O y (-CH2-)m; donde R9 y R10 se seleccionan independientemente entre hidrogeno o alquilo C1-6 y donde dicho alquilo C1-6 está opcionalmente sustituido con uno o más R19; y donde m es 0, 1, 2 o 3 y donde z es 1 o 2; R6 se selecciona entre -O-, -N(R11)C(O)-, -C(O)N(R12)-, -S(O)r-, -SO2N(R13)-, -N(R14)SO2-, -(CH2)pN(R15)-, -OSO2-, -C(O)-, -C(O)O-, -N(R16)C(O)O-, -N(R17)C(O)N(R18)- y (-CH2-)n; donde R11, R12, R13, R14, R15, R16, R17 y R18 se seleccionan independientemente entre hidrogeno o alquilo C1-6 y donde dicho alquilo C1-6 está opcionalmente sustituido con uno o más R19; y donde n es 0, 1, 2 o 3 y donde p es 0, 1, 2 o 3 y donde r es 0, 1 o 2; R7 se selecciona entre hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -alquil C1-4carbociclilo, -alquil C1-4heterociclilo, carbociclilo y heterociclilo; donde R7 puede estar opcionalmente sustituido en carbono con uno o más R20; y donde si dicho heterociclilo contiene una porcion -NH-, ese nitrogeno puede estar opcionalmente sustituido con un grupo seleccionado entre R21; R19 y R20 se seleccionan independientemente entre halo, nitro, ciano, hidroxi, amino, carboxi, carbamoilo, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcoxi C1- 6-alcoxi C1-6, alcanoílo C1-6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, alcanoilamino C1-6, N-(alquil C1-6)carbamoilo, N,N(alquil C1-6)2carbamoílo, alquil C1-6S(O)a, alcoxi C1-6carbonilo, N(alquil C1-6)sulfamoilo, N,N-(alquil C1-6)2sulfamollo, alquil C1-6sulfonilamino, carbociclilo, heterociclilo, carbociclilalquil C1-6-R22-, heterociclilalquil C1-6-R23-, carbociclil-R24- y heterociclil-R25-; donde a es 0, 1 o 2; y donde R19 y R20 independientemente uno del otro, está opcionalmente sustituido en carbono con uno o más R26; y donde si dicho heterociclilo contiene una porcion -NH-, ese nitrogeno está opcionalmente sustituido con un grupo seleccionado entre R27; R22, R23, R24 y R25 se seleccionan independientemente entre -O-, - N(R28)-, -C(O)-, -N(R29)C(O)-, -C(O)N(R30)-, -S(O)s-, -SO2N(R31)- y -N(R32)SO2-; donde R28, R29, R30, R31 y R32 se seleccionan independientemente entre hidrogeno o alquilo C1-6 y s es 0, 1 o 2; R21 y R27 se seleccionan independientemente entre alquilo C1-6, alcanoílo C1-6, alquil C1-6sulfonilo, alcoxi C1-6carbonilo, carbamoilo, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)carbamoilo, carbociclilo, heterociclilo, -alquil C1-6carbociclilo, -alquil C1-6heterociclilo, benciloxicarbonilo, benzoilo y fenilsulfonilo; donde R21 y R27 independientemente uno del otro, están opcionalmente sustituido en carbono con uno o más R33; y R26 y R33 se seleccionan independientemente entre halo, nitro, ciano, -alquil C1-3hidroxi, -alquil C1-3metoxi, -alquil C1-3etoxi, -alquil C1-3isopropoxi, hidroxi, trifluorometoxi, trifluorometilo, amino, carboxi, carbamoilo, mercapto, sulfamoilo, metilo, etilo, ciclopropilo, ciclobutilo, metoxi, etoxi, acetilo, acetoxi, metilamino, etilamino, dimetilamino, dietilamino, N-metil-N-etilamino, acetilamino, N-metilcarbamoilo, N-etilcarbamoilo, N,N-dimetilcarbamoilo, N,N-dietilcarbamoilo, N-metil-N-etilcarbamoilo, metiltio, etiltio, metilsulfinilo, etilsulfinilo, mesilo, etilsulfonilo, metoxicarbonilo, etoxicarbonilo, N-metilsulfamoilo, N-etilsulfamoilo, N,N-dimetilsulfamoilo, N,N-dietilsulfamoilo, N-metil-N-etilsulfamoilo, carbociclo y heterociclo; donde dicho carbociclo o heterociclo está opcionalmente sustituido con halo, metilo, trifluorometilo, ciano o etilo; como una base libre o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81675506P | 2006-06-27 | 2006-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR061653A1 true AR061653A1 (es) | 2008-09-10 |
Family
ID=38846128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102832A AR061653A1 (es) | 2006-06-27 | 2007-06-26 | Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3) |
Country Status (19)
Country | Link |
---|---|
US (1) | US20080188503A1 (es) |
EP (1) | EP2046783A4 (es) |
JP (1) | JP2009542639A (es) |
KR (1) | KR20090024295A (es) |
CN (1) | CN101511824A (es) |
AR (1) | AR061653A1 (es) |
AU (1) | AU2007265732A1 (es) |
BR (1) | BRPI0713578A2 (es) |
CA (1) | CA2655444A1 (es) |
CL (1) | CL2007001882A1 (es) |
EC (1) | ECSP088974A (es) |
IL (1) | IL195665A0 (es) |
MX (1) | MX2008015721A (es) |
NO (1) | NO20090328L (es) |
RU (1) | RU2008148903A (es) |
TW (1) | TW200815417A (es) |
UY (1) | UY30438A1 (es) |
WO (1) | WO2008002245A2 (es) |
ZA (1) | ZA200810577B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY29826A1 (es) | 2005-09-30 | 2007-04-30 | Astrazeneca Ab | Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones |
TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CA2761064A1 (en) * | 2009-04-15 | 2010-10-21 | Astrazeneca Ab | Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2012050517A1 (en) * | 2010-10-14 | 2012-04-19 | Astrazeneca Ab | Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2016008966A1 (en) | 2014-07-17 | 2016-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating neuromuscular junction-related diseases |
WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
KR102206111B1 (ko) | 2019-04-01 | 2021-01-22 | 박광호 | 목욕탕용 담수 및 해수 가열시스템 |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
MX2022001940A (es) | 2019-08-14 | 2022-05-10 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2. |
PE20221905A1 (es) | 2019-10-11 | 2022-12-23 | Incyte Corp | Aminas biciclicas como inhibidoras de la cdk2 |
CN116472270A (zh) * | 2021-02-05 | 2023-07-21 | 上海齐鲁制药研究中心有限公司 | Cdk抑制剂 |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
WO2004005283A1 (en) * | 2002-07-09 | 2004-01-15 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
WO2005012298A1 (en) * | 2003-07-30 | 2005-02-10 | Cyclacel Limited | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
CA2542880A1 (en) * | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
BRPI0517426A (pt) * | 2004-12-17 | 2008-10-07 | Astrazeneca Ab | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente |
GB0504753D0 (en) * | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
UY29827A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones |
TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
-
2007
- 2007-06-21 TW TW096122335A patent/TW200815417A/zh unknown
- 2007-06-26 EP EP07748282A patent/EP2046783A4/en not_active Withdrawn
- 2007-06-26 MX MX2008015721A patent/MX2008015721A/es not_active Application Discontinuation
- 2007-06-26 WO PCT/SE2007/000621 patent/WO2008002245A2/en active Application Filing
- 2007-06-26 CL CL200701882A patent/CL2007001882A1/es unknown
- 2007-06-26 UY UY30438A patent/UY30438A1/es unknown
- 2007-06-26 KR KR1020097001643A patent/KR20090024295A/ko not_active Application Discontinuation
- 2007-06-26 CA CA002655444A patent/CA2655444A1/en not_active Abandoned
- 2007-06-26 RU RU2008148903/04A patent/RU2008148903A/ru not_active Application Discontinuation
- 2007-06-26 JP JP2009518045A patent/JP2009542639A/ja active Pending
- 2007-06-26 AR ARP070102832A patent/AR061653A1/es not_active Application Discontinuation
- 2007-06-26 BR BRPI0713578-5A patent/BRPI0713578A2/pt not_active IP Right Cessation
- 2007-06-26 AU AU2007265732A patent/AU2007265732A1/en not_active Abandoned
- 2007-06-26 CN CNA2007800320192A patent/CN101511824A/zh active Pending
- 2007-06-27 US US11/769,113 patent/US20080188503A1/en not_active Abandoned
-
2008
- 2008-12-02 IL IL195665A patent/IL195665A0/en unknown
- 2008-12-12 EC EC2008008974A patent/ECSP088974A/es unknown
- 2008-12-12 ZA ZA200810577A patent/ZA200810577B/xx unknown
-
2009
- 2009-01-21 NO NO20090328A patent/NO20090328L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CL2007001882A1 (es) | 2008-02-08 |
TW200815417A (en) | 2008-04-01 |
WO2008002245A3 (en) | 2008-02-14 |
CA2655444A1 (en) | 2008-01-03 |
AU2007265732A1 (en) | 2008-01-03 |
IL195665A0 (en) | 2009-09-01 |
RU2008148903A (ru) | 2010-08-10 |
EP2046783A4 (en) | 2010-08-04 |
WO2008002245A8 (en) | 2008-10-09 |
CN101511824A (zh) | 2009-08-19 |
UY30438A1 (es) | 2008-01-31 |
MX2008015721A (es) | 2009-01-08 |
KR20090024295A (ko) | 2009-03-06 |
US20080188503A1 (en) | 2008-08-07 |
ZA200810577B (en) | 2009-08-26 |
EP2046783A2 (en) | 2009-04-15 |
WO2008002245A2 (en) | 2008-01-03 |
JP2009542639A (ja) | 2009-12-03 |
BRPI0713578A2 (pt) | 2012-10-23 |
ECSP088974A (es) | 2009-01-30 |
NO20090328L (no) | 2009-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR061653A1 (es) | Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3) | |
AR055249A1 (es) | Derivados de quinazolinas, procesos de obtencion y composiciones farmaceuticas | |
AR050545A1 (es) | Derivados de quinazolinonas y su uso como inhibidores de b-raf | |
AR064208A1 (es) | Derivados de piridin-3-il-quinazolinas como inhibidores de b-raf. procesos de obtencion y composiciones farmaceuticas. | |
AR049662A1 (es) | Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer | |
AR054183A1 (es) | Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas. | |
AR070493A1 (es) | Derivados heterociclicos de urea, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones bacterianas. | |
AR053683A1 (es) | Derivados de piperidina con actividad antibacteriana | |
AR056184A1 (es) | Compuestos derivados de pirazol, composicion farmaceutica en base a aquellos y su uso para la fabricacion de medicamentos | |
AR056556A1 (es) | Imidazo(1,2-a)piridina con actividad antiproliferacion celular | |
AR061652A1 (es) | Derivados de pirimidina, un metodo para su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprenden y el uso de los mismos en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de gsk3. | |
AR072045A1 (es) | Derivados heterociclicos de urea y metodos para utilizarlos | |
AR047702A1 (es) | Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular | |
AR053992A1 (es) | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. | |
AR056210A1 (es) | 4-(3-aminopirazol)pirimidina para uso como inhibidores de tirosina-quinasa | |
AR062406A1 (es) | Derivados de quinazolina como inhibidores de b-raf | |
AR041594A1 (es) | Derivados de 1,4 piperidina disustituida y su uso como inhibidores de 11-beta hidroxiesteroide dehidrogenasa tipo 1 | |
AR046616A1 (es) | Piperidinas sustituidas utiles en el tratamiento de sindrome metabolico | |
AR077971A1 (es) | Derivados heterociclicos de urea y metodos de uso de los mismos | |
AR052170A1 (es) | Derivados de pirimidina utiles por su actividad anti-proliferacion celular | |
AR046615A1 (es) | Pirrolidinas 3-(benzoil)-n-aciladas, como inhibidores de 11-beta-hsd1, utiles en el tratamiento de desordenes metabolicos | |
AR072047A1 (es) | Compuestos heterociclicos utiles para inhibir la adn girasa | |
AR056354A1 (es) | DERIVADOS DE PIRAZOL, UN MÉTODO DE PREPARACIoN DEL COMPUESTO, COMPOSICIoN FARMACÉUTICA Y PREPARACIoN DE UN MEDICAMENTO | |
AR064130A1 (es) | Derivados de tiazoles y piridinas como antibacterianos. composiciones farmaceuticas. | |
AR076899A1 (es) | Derivados heterociclicos de la urea, composiciones farmaceuticas y su uso en el tratamiento de infecciones bacterianas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |